PD-L1 testing and immunotherapy selection - early laboratory experience and its potential role in head and neck cancer management.
PD-L1 testing and immunotherapy selection - early laboratory experience and its potential role in head and neck cancer management.
复制标题
PD -L1测试和免疫疗法选择 - 早期实验室经验及其在头颈癌管理中的潜在作用。
DOI：
10.22551/2021.30.0801.10179
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Chaturvedi A
中科院分区：
文献类型：
--
作者：
Bancu A;Cowan R;Chaturvedi A
抗程序性细胞死亡蛋白-1（PD-1）治疗最近已被NICE批准用于治疗复发性和转移性头颈部鳞状细胞癌（HNSCC）。在这种情况下，伴随诊断程序性细胞死亡配体-1（PD-L1）测试，以前在我们的中心建立肺和膀胱肿瘤，在一些头颈癌病例进行。本研究的范围是审核相关的PD-L1数据，并将结果整合到我们当前的临床实践中，以期促进HNSCC常规实验室生物标志物的改善。本研究纳入了记录肿瘤类型、PD-L1结果和克隆/检测类型的组织学报告。在5年的时间里，在199例癌症病例中进行了PD-L1检测，其中包括3例低局灶性阳性染色的头颈部鳞状细胞癌。HNSCC的免疫疗法治疗显示PD-L1阳性受试者的总生存期得到了谨慎但仍然显着的改善。
Anti-programmed cell death protein-1 (PD-1) therapy has been relatively recently approved in a defined context by NICE in adults in the management of recurrent and metastatic head and neck squamous cell carcinomas (HNSCC). In this context, companion diagnostic programmed cell death ligand-1 (PD-L1) testing, previously established at our center for lung and bladder tumors, was undertaken in a few head and neck cancer cases. The scope of this study was to audit the relevant PD-L1 data and integrate the findings in our current clinical practice, with a view to promote improved routine laboratory biomarkers in HNSCC. Histopathology reports documenting tumor type, PD-L1 result and type of clone/assay were included in this study. Over a 5-year period, PD-L1 testing was undertaken in 199 cancer cases, including 3 with head and neck squamous carcinoma with low focal positive staining. Immunotherapy treatment in HNSCC demonstrates a discreet but still significant improvement in the overall survival of PD-L1 positive subjects.
登录
查看更多内容
头颈癌的预后因素：意大利单一机构的10年回顾性分析。
DOI：
10.14639/0392-100x-1246
发表时间：
2017-12
期刊：
Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale
影响因子：
--
作者：
Cadoni G;Giraldi L;Petrelli L;Pandolfini M;Giuliani M;Paludetti G;Pastorino R;Leoncini E;Arzani D;Almadori G;Boccia S
通讯作者：
Boccia S
影响因子：
3
作者：
Denaro N;Merlano MC;Russi EG
通讯作者：
Russi EG
影响因子：
4.6
作者：
Kim HS;Lee JY;Lim SH;Park K;Sun JM;Ko YH;Baek CH;Son YI;Jeong HS;Ahn YC;Lee MY;Hong M;Ahn MJ
通讯作者：
Ahn MJ
头颈癌中 PD-1/PD-L1 通路的演变
影响因子：
7.3
作者：
Qiao XW;Jiang J;Pang X;Huang MC;Tang YJ;Liang XH;Tang YL
通讯作者：
Tang YL
影响因子：
5.8
作者：
Pulte, Dianne;Brenner, Hermann
通讯作者：
Brenner, Hermann